Company intelligence / Profile preview

UWELL Biopharma

Ownership: Private
Development stage: Other

Overview

UWELL Biopharma has advanced a portfolio of autologous CAR-T therapies targeting hematological tumors. Its lead candidate UWC19 targets CD19-positive hematologic malignancies and has reached Phase II for lymphoblastic lymphoma. Preclinical data show effective elimination of CD19-positive tumor cells with a favorable toxicity profile. The company also developed NKG2D-targeted CAR-T therapies that have shown robust antitumor efficacy in xenograft models but were discontinued in clinical development for glioblastoma.

Therapeutic areas: HematologyOncology
Modalities: Autologous CAR-T cell therapyCAR-NK cell therapy
Industry: Biotech

Drug pipeline

6 assets

UBP-3004

Preclinical

5 more assets in the full pipeline.

Partnerships

Collaborations with clinical teams and partners in Taiwan, China, Malaysia

Beyond the preview

Go deeper on UWELL Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UWELL Biopharma.